<DOC>
	<DOCNO>NCT02048800</DOCNO>
	<brief_summary>Every year around 70 child affect cancer life-threatening genetic disease undergo haematopoietic cell transplantation ( HCT ) within Blood Marrow Transplant ( BMT ) unit Great Ormond Street Hospital ( GOSH ) . One main goal BMT unit last decade reduce morbidity mortality relate HCT , group become world-leader pioneering less toxic transplant . Fixed high dos chemotherapy drug generally use prepare child HCT several study show correlation concentration drug achieve patient 's blood , success failure HCT procedure . Recently new drug , Treosulfan , become available use patient undergo HCT , GOSH pioneer introduction child undergo HCT . With promising early result , Treosulfan become pre-HCT drug choice , however , little currently know drug metabolise clear body , particularly child . The investigator therefore plan investigate pharmacokinetic ( PK ) profile Treosulfan child undergo HCT GOSH define parameter affect metabolism clearance , blood level associate favourable outcome ( graft take without toxicity ) poor result ( graft rejection and/or toxicity ) .</brief_summary>
	<brief_title>Treosulfan Pharmacokinetics Children Undergoing Allogeneic HSCT</brief_title>
	<detailed_description />
	<mesh_term>Treosulfan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>1. age ≥ 28 day ≤ 18 year old ; 2 . Karnofsky Performance Status ≥ 50 Lansky Performance Status ≥ 30 ; 3. provide sign , write informed consent parent guardian ; 4. able comply study procedure followup examination ; 5. adequate organ function ( indicate Table 1 , page 27 ) , within 14 day prior enrollment ; 6. negative pregnancy test postpubertal female patient . 1. patient age &lt; 28 day &gt; 18 year old ; 2. patient compromise organ function* ; 3. patient severe concurrent disease , , judgment Investigator , would make patient inappropriate entry study ; 4. know hypersensitivity Treosulfan Fludarabine ; 5. pregnancy/lactation .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Treosulfan pharmacokinetics</keyword>
	<keyword>Children</keyword>
	<keyword>Any condition require allogeneic HSCT</keyword>
</DOC>